Dergiler / Maltepe Tıp Dergisi / 2026 / Cilt: 12 Sayı: 1

New Aspects of Pulmonary Tuberculosis

Nesrin Sarıman(Maltepe Üniversitesi Tıp Fakültesi)0000-0003-3311-3338
Selim Nalbant(Maltepe Üniversitesi Tıp Fakültesi)
Sayfa
23–26
Yayın Tarihi
2020-04-30
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this article recent developments in tuberculosis diagnostics, new anti tuberculosis drugs and vaccines for tuberculosis have been summarized.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:There is a worldwide rise in tuberculosis (TB) cases with drug resistant strains being a threat to disease control with the current measures.
📊
Temel Bulgular & Veri:In recent years novel antituberculosis drug candidates and vaccines have entered clinical trials.
💡
Sonuç & Katkı:In this article recent developments in tuberculosis diagnostics, new anti tuberculosis drugs and vaccines for tuberculosis have been summarized.
🔬Tür:Derleme
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:pulmonary tuberculosis · new antitubrerculosis drugs · drug resistance

Özet

There is a worldwide rise in tuberculosis (TB) cases with drug resistant strains being a threat to disease control with the current measures. In recent years novel antituberculosis drug candidates and vaccines have entered clinical trials. Besides their activity against multi drug and extensively drug resistant strains they also target to reduce the treatment period and dosing. In this article recent developments in tuberculosis diagnostics, new anti tuberculosis drugs and vaccines for tuberculosis have been summarized.

Abstract

There is a worldwide rise in tuberculosis (TB) cases with drug resistant strains being a threat to disease control with the current measures. In recent years novel antituberculosis drug candidates and vaccines have entered clinical trials. Besides their activity against multi drug and extensively drug resistant strains they also target to reduce the treatment period and dosing. In this article recent developments in tuberculosis diagnostics, new anti tuberculosis drugs and vaccines for tuberculosis have been summarized.

🔖

Bu Makaleye Atıf Yap

Sarıman, N. (2020). New Aspects of Pulmonary Tuberculosis. Maltepe Tıp Dergisi, Cilt: 12 Sayı: 1, 23–26. https://doi.org/10.35514/mtd.2020.25

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. WHO. Global tuberculosis report 2014. World Health Organization, Geneva (2014) http://www.who.int/tb/publications/global_report/en/ (accessed Nov 12, 2014).
  2. Ralph AP, Anstey NM, Kelly PM. Tuberculosis into the 2010s: Is the Glass Half Full? Clin Infect Dis. 2009; 49 (4): 574-583.
  3. Amicosante M, Ciccozzi M, Markova R. Rational use of immunodiagnostic tools for tuberculosis infection: guidelines and cost effectiveness studies. New Microbiol 2010; 33 (2):93-107.
  4. Weiner J 3rd, Kaufmann SH. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med. 2014;275(5):467-480. doi: 10.1111/joim.12212.
  5. Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy.Drug Discov Today 2006;11(1-2):21-27.
  6. Lougheed KE, Taylor DL, Osborne SA, Bryans JS, Buxton RS. New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb). 2009 Sep;89(5):364-370. doi: 10.1016/j.tube.2009.07.002.
  7. Balganesh TS, Alzari PM, Cole ST. Rising standards for tuberculosis drug development. Trends Pharmacol Sci 2008 Nov;29(11):576-581.
  8. Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today. 2008 Dec;13(23-24):1090 -1098. doi: 10.1016/j.drudis.2008.09.004.
  9. Grandjean L, AJ Moore D. Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug resistant tuberculosis (XDR-TB) Curr Opin Infect Dis. 2008; 21(5): 454-461. doi:10.1097/QCO.0b013e32830ce783.
  10. Janin YL. Antituberculosis drugs: Ten years of research.Bioorg Med Chem 2007; 1;15(7):2479-513.
  11. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization; 2013. WHO Guidelines Approved by the Guidelines Review Committee
  12. Kaufman SH, Weiner J, von Reyn CF. Novel approaches to tuberculosis vaccine developmentInt Int J Infect Dis. 2017; 56: 263-267. doi: 10.1016/j.ijid.2016.10.018